US Patent 12,377,176: What Do the Claims Actually Cover and How Broad Is the Patent Landscape?
United States Patent 12,377,176 is a compound-centric and conjugate-centric cancer application patent. The claims are written to protect (1) the specific chemical structure (Claim 1), then (2) use of that compound in pharmaceutical/diagnostic compositions (Claim 2), and (3) cancer imaging, cancer treatment, and anti-angiogenesis methods through administering the claimed conjugate (Claims 3-6). The practical scope hinges on whether the “conjugate” in the specification is tightly defined (single linker/target payload) or broadly defined (class-level conjugation). Based on the provided claim set alone, the claims are broad on indication format (imaging, treating, angiogenesis reduction) but narrow on what is being administered (a conjugate that “accord[es] with claim 1,” i.e., built on the chemical structure of Claim 1).
What is the claim structure: compound → conjugate → methods?
The independent premise across Claims 2-6 is consistent: everything flows from Claim 1.
| Claim |
Claim category |
Core requirement |
Practical effect on scope |
| 1 |
Product (compound) |
“A compound having a chemical structure … or a pharmaceutically acceptable salt” |
Anchors infringement to the exact claimed structure (or salt). Breadth depends on structure definition in the claim text/spec. |
| 2 |
Composition |
“A pharmaceutical or diagnostic composition comprising or consisting of one or more conjugates in accordance with claim 1” |
Extends product protection into formulation and diagnostic use. Still limited by conjugates that track Claim 1. |
| 3 |
Imaging/diagnosis method |
“Administering a conjugate according to claim 1” |
Covers imaging/diagnostic administration where the administered entity is the claimed conjugate. |
| 4 |
Treatment method |
“Administering a conjugate according to claim 1” |
Broad cancer treatment hook, since “cancer” is not limited to subtypes. |
| 5 |
Angiogenesis reduction |
“Reducing neoangiogenesis/angiogenesis” via administering the conjugate |
Adds a mechanistic/biological endpoint; still limited to the claimed conjugate. |
| 6 |
Treatment method with tumor type limit |
Cancer is prostate, breast, lung, colorectal, or renal cell carcinoma |
Narrows Claim 4 to five enumerated indications. |
What does Claim 1 actually lock down: structure or class?
Claim 1 is the keystone: “A compound having a chemical structure: [structure] or a pharmaceutically acceptable salt thereof.” In US practice, such language typically means infringement is evaluated by structural identity (or equivalence doctrines where applicable), not by broad genus coverage.
Scope implications of “chemical structure” claim language
- Product scope is structure-defined. If the chemical structure in Claim 1 is specific (as written), the claim is generally not a flexible Markush genus at the claim level.
- Salts are included. “Pharmaceutically acceptable salt thereof” extends the coverage beyond free base/acid form to approved or acceptable salt forms.
- If the claim includes only one structure: competitors cannot avoid infringement by selecting a different payload or linker while keeping the conjugate centered on Claim 1 structure (but they may avoid by using a meaningfully different compound/conjugate not “in accordance with claim 1”).
Where the scope can expand or contract
The claim set you provided does not show the actual chemical structure depicted in Claim 1, nor does it show the definition of “conjugate.” In patent claim interpretation, those definitions typically live in:
- the specification definitions of “conjugate,”
- the claim language where conjugate components are described,
- and any dependent claims that specify linker, targeting moiety, payload, or chemistry.
Without that text, the only defensible statement from the claim set is: Claims 2-6 are limited to conjugates that are “in accordance with claim 1.”
How broad is Claim 2: does it cover any formulation or only conjugate-containing products?
Claim 2 covers: “A pharmaceutical or diagnostic composition comprising or consisting of one or more conjugates in accordance with claim 1.”
Scope is formulation-agnostic but conjugate-limited
- The claim does not limit excipients, concentration ranges, administration routes, or device formats.
- It also includes the “consisting of” option, which can matter in some enforceability contexts because it can bar compositions containing additional conjugates not encompassed by the claim (while still limiting to the claimed conjugate).
Business implication: a competitor making a diagnostic formulation or therapeutic formulation with the same claimed conjugate risks direct claim coverage under Claim 2, even if the formulation differs (unless it avoids having a conjugate “in accordance with claim 1”).
What does Claim 3 cover: imaging/diagnosis without specifying cancer type or imaging modality?
Claim 3: “A method of imaging and/or diagnosing cancer comprising administering a conjugate according to claim 1 to a patient…”
Scope characteristics
- No imaging modality is specified (e.g., PET, SPECT, MRI, fluorescence). The method is broad because it only requires imaging/diagnosing cancer using the claimed conjugate.
- No cancer subtype is specified. It covers “cancer” generally.
- No route or regimen is specified (unless defined elsewhere). The “administering” language is typically broad.
Business implication: the claim can reach any clinical protocol where the claimed conjugate is administered for imaging or diagnosis of cancer.
How strong is Claim 4: broad “treating cancer” method with minimal limits
Claim 4: “A method of treating cancer comprising administering a conjugate according to claim 1…”
Why this is legally and commercially relevant
- It is method-of-treatment language, anchored on a conjugate.
- It is not limited to a specific line of therapy (first-line, salvage) and not limited to specific tumor biology (no restriction to angiogenesis-driving tumors in the claim).
- It covers any “patient in need thereof,” which is common for method claims.
Business implication: if the claimed conjugate is used in oncology treatment in any tumor type, Claim 4 is a central enforcement target.
What extra value does Claim 5 add: “reducing neoangiogenesis/angiogenesis”
Claim 5: “A method of reducing neoangiogenesis/angiogenesis comprising administering a conjugate according to claim 1…”
Scope effect
- Claim 5 adds a biological endpoint that can support enforcement in cases where the clinical protocol is framed around anti-angiogenic activity.
- Claim 5 is still limited to administration of the conjugate of Claim 1.
Business implication: if the sponsor markets or prosecutes the clinical program as anti-angiogenic, Claim 5 strengthens narrative alignment for infringement arguments (particularly for claims directed to functional outcomes). It does not, by itself, expand the conjugate scope.
How narrow is Claim 6: enumerated tumor types
Claim 6 narrows Claim 4 to: prostate, breast, lung, colorectal, or renal cell carcinoma.
Scope effect
- It is narrower than Claim 4 but provides explicit coverage for common oncology indications.
- The enumerated list can be used defensively to preserve claim validity and to support enforceability for specific targets.
Business implication: if a competitor focuses on one of these five indications, Claim 6 gives a tighter infringement path even if broader “cancer” language is contested.
What does this mean for the patent landscape in practice?
1) Where this patent sits in freedom-to-operate (FTO)
The claim set is typical of a compound and conjugate platform patent: it creates a wall around products and methods that use the same claimed conjugate.
FTO-critical “infringement gates”
To infringe Claims 2-6, an accused product or protocol generally must satisfy:
- Conjugate identity requirement: the administered conjugate must be “in accordance with claim 1.”
- Use context requirement (for methods):
- Claim 3: imaging/diagnosing cancer
- Claim 4: treating cancer
- Claim 5: reducing angiogenesis
- Claim 6: treating specific tumor types
If an accused agent differs structurally from Claim 1, it may fall outside. If it matches Claim 1 but is used for non-cancer indications, Claim 4 may not be triggered, but Claim 2 (composition) could still be a coverage driver.
2) Practical enforcement leverage
This patent likely provides enforcement leverage across multiple clinical program activities because it covers:
- formulation (Claim 2),
- diagnostics (Claim 3),
- therapeutics (Claim 4),
- mechanistic claim framing (Claim 5),
- and explicit oncology tumor types (Claim 6).
That breadth increases the number of “entry points” for infringement allegations: manufacturing, clinical use, and marketing for imaging or treatment indications.
3) Key competitive design-around paths
Given the claim language provided, the only legally significant avoidance mechanism is to ensure the accused conjugate is not “in accordance with claim 1.” Competitors typically attempt:
- changing the conjugate’s core chemical scaffold (to move out of Claim 1),
- changing salt form (less likely to avoid because salts are included),
- shifting to a different conjugate platform entirely (target, linker chemistry, or payload architecture) so the administered entity is not within Claim 1.
Changing the indication (outside “cancer”) does not neutralize Claims 2-3 if they are used for imaging/diagnosing cancer. Changing dosing regimen is unlikely to defeat the method claims if “administering” is still present.
Scope comparison: which claims are the broadest and most valuable?
| Rank (broadest to narrowest) |
Claim |
Why it is broad |
Main limiter |
| 1 |
Claim 4 |
“treating cancer” is generic |
Requires conjugate “in accordance with claim 1” |
| 2 |
Claim 3 |
imaging/diagnosis of “cancer” is generic |
Requires conjugate “in accordance with claim 1” |
| 3 |
Claim 2 |
composition is not tied to route, dose, or excipients |
Requires conjugate(s) “in accordance with claim 1” |
| 4 |
Claim 5 |
adds anti-angiogenic functional endpoint |
Requires conjugate “in accordance with claim 1” |
| 5 |
Claim 6 |
only five tumor types |
Requires conjugate “in accordance with claim 1” and enumerated cancers |
| (Product anchor) |
Claim 1 |
structure-defined |
depends on exact structure in claim text/spec |
What is missing from the claim excerpt that drives the true landscape?
A complete patent landscape requires: the identity of the chemical structure in Claim 1 and the precise definition of “conjugate.” Those details determine whether:
- the claim reads on a known radiopharmaceutical/targeting ligand platform,
- the claim covers a linker class or a specific linker,
- and whether the conjugate has components that other patents would overlap with.
Because those specifics are not included in the prompt, the landscape analysis here stays at the enforceability level dictated by claim language: compound-defined, conjugate-administering methods, with general cancer coverage and explicit tumor-type dependency in Claim 6.
Key Takeaways
- US 12,377,176 is claim-structured as Claim 1 (compound) controlling Claims 2-6 (conjugate compositions and cancer-related methods).
- Claims 3 and 4 are broad because they cover imaging and treatment of “cancer” without specifying modality or tumor subtype.
- Claim 5 adds an anti-angiogenesis endpoint but does not expand beyond the same conjugate anchor.
- Claim 6 provides tighter coverage for prostate, breast, lung, colorectal, and renal cell carcinoma, useful for targeted enforcement.
- The practical design-around is chemical: avoid making or using a conjugate that is “in accordance with claim 1.” Salt form and indication shifts alone are unlikely to remove exposure if the claimed conjugate is used for cancer imaging or treatment.
FAQs
1) Are the method claims limited to specific cancer imaging technologies (PET/SPECT/MRI)?
No. The claim language provided only requires imaging/diagnosing cancer via administering the conjugate.
2) Does Claim 2 cover only therapeutic formulations or also diagnostic ones?
It covers both: “pharmaceutical or diagnostic composition.”
3) If a company uses the conjugate for non-cancer indications, can Claims 3-6 be avoided?
Claims 3-6 require “cancer” in the method context as stated; non-cancer use is outside those method claim triggers as written, while Claim 2 may remain relevant for compositions.
4) Is the claim limited to one tumor type?
No. Claim 4 covers “cancer” generally; Claim 6 limits to five tumor types as a dependent narrowing.
5) Is avoiding by using a different salt form effective?
Claim 1 includes “pharmaceutically acceptable salt,” so switching to an alternative acceptable salt does not avoid coverage if it still falls within Claim 1’s compound family.
References
[1] United States Patent 12,377,176 (claims 1-6 as provided in prompt).
